Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

BMC Psychiatry

Volumn 8, Issue , 2008, Pages

  Lipkovich, Ilya ^a   Jacobson, Jennie G ^a   Hardy, Thomas A ^a   Hoffmann, Vicki Poole ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ARTICLE; BODY MASS; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; POPULATION RISK; PREDICTION; RISK ASSESSMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SMOKING; TREATMENT DURATION; WEIGHT GAIN; ADULT; FEMALE; MALE; OBESITY; PSYCHOSIS; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; FEMALE; HUMANS; MALE; OBESITY; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 54049084583     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-8-78     Document Type: Article

References (28)

1. Blanck HM Dietz WH Galuska DA Gillespie C Hamre R Kahn LK Serdula MK Ford ES Garvin WS Mokdad AH Densmore D State-specific prevalence of obesity among adults - United States, 2005 MMWR Morb Mortal Wkly Rep 2006, 55(36):985-988. 16971886
2. Gregg EW Cadwell BL Cheng YJ Cowie CC Williams DE Geiss L Engelgau MM Vinicor F Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S Diabetes Care 2004, 27(12):2806-2812. 10.2337/diacare.27.12.2806 15562189
3. Goff DC Cather C Evins AE Henderson DC Freudenreich O Copeland PM Beirer M Duckworth K Sacks FM Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists J Clin Psychiatry 2005, 66(2):183-194. 15705003
4. Curkendall SM Mo J Glasser DB Rose Stang M Jones JK Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada J Clin Psychiatry 2004, 65(5):715-720. 15163261
5. Megna JL Raj Kunwar A Wade MJ A retrospective study of weight changes and the contributing factors in short term adult psychiatric inpatients Ann Clin Psychiatry 2006, 18(3):163-167. 10.1080/10401230600801168 16923654
6. Daumit GL Goldberg RW Anthony C Dickerson F Brown CH Kreyenbuhl J Wohlheiter K Dixon LB Physical activity patterns in adults with severe mental illness J Nerv Ment Dis 2005, 193(10):641-646. 10.1097/ 01.nmd.0000180737.85895.60 16208158
7. Sokal J Messias E Dickerson FB Kreyenbuhl J Brown CH Goldberg RW Dixon LB Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services J Nerv Ment Dis 2004, 192(6):421-427. 10.1097/01.nmd.0000130135.78017.96 15167405
8. Thakore JH Metabolic disturbance in first-episode schizophrenia Br J Psychiatry Suppl 2004, 47:S76-S79. 10.1192/bjp.184.47.s76 15056598
9. Ascher-Svanum H Stensland M Zhao Z Kinon BJ Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia BMC Psychiatry 2005, 5:3. 547901 15649317 10.1186/ 1471-244X-5-3
10. Meltzer HY Perry E Jayathilake K Clozapine-induced weight gain predicts improvement in psychopathology Schizophr Res 2003, 59(1):19-27. 10.1016/ S0920-9964(01)00326-7 12413638
11. Gasquet I Haro JM Novick D Edgell ET Kennedy L Lepine JP SOHO Study Group Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: Results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study Int Clin Psychopharmacol 2005, 20(4):199-205. 10.1097/ 00004850-200507000-00002 15933480
12. Lieberman JA Stroup TS McEvoy JP Swartz MS Rosenheck RA Perkins DO Keefe RS Davis SM Davis CE Lebowitz BD Severe J Hsaio JK Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 2005, 353(12):1209-1223. 10.1056/NEJMoa051688 16172203
13. Ascher-Svanum H Nyhuis AW Faries DE Kinon BJ Baker RW Shekhar A Clinical, functional, and economic ramifications of early non-response to antipsychotics in the naturalistic treatment of schizophrenia Schizophr Bull 2007 Advanced Access published December 21.
14. Kinon BJ Chen L Ascher-Svanum H Stauffer V Kollack-Walker S Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia American Psychiatric Association, San Diego; 2007.
15. Lipkovich I Citrome L Perlis R Deberdt W Houston JP Ahl J Hardy T Early predictors of substantial weight gain in bipolar patients treated with olanzapine J Clin Psychopharmacol 2006, 26(3):316-320. 10.1097/ 01.jcp.0000219916.88810.1c 16702898
16. Kinon BJ Kaiser CJ Ahmed S Rotelli M Kollack-Walker S Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders J Clin Psychopharmacol 2005, 25(3):255-258. 10.1097/ 01.jcp.0000161501.65890.22 15876905
17. Tollefson GD Beasley CM Jr Tran PV Street JS Krueger JA Tamura RN Graffeo KA Thieme MA Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial Am J Psychiatry 1997, 154(4):457-465. 9090331
18. Tran PV Hamilton SH Kuntz AJ Potvin JH Andersen SW Beasley C Jr Tollefson GD Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders J Clin Psychopharmacol 1997, 17(5):407-418. 10.1097/00004714-199710000-00010 9315992
19. Kinon BJ Basson BR Gilmore JA Tollefson GD Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia J Clin Psychiatry 2001, 62(2):92-100. 11247108
20. Wirshing DA Wirshing WC Kysar L Berisford MA Goldstein D Pashdag J Mintz J Marder SR Novel antipsychotics: Comparison of weight gain liabilities J Clin Psychiatry 1999, 60(6):358-363. 10401912
21. Basson BR Kinon BJ Taylor CC Szymanski KA Gilmore JA Tollefson GD Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone J Clin Psychiatry 2001, 62(4):231-238. 11379836
22. Rubin DB Multiple imputations in sample surveys - A Phenomenological Bayesian Approach To Nonresponse Proceedings for the Survey Research Methods Section, American Statistical Association Washington DC, American Statistical Association 1978:20-34.
23. Rubin DB Multiple Imputation for Nonresponse in Surveys New York: John Wiley & Sons, Inc; 1987.
24. Brar JS Ganguli R Pandina G Turkoz I Berry S Mahmoud R Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder J Clin Psychiatry 2005, 66(2):205-212. 15705006
25. Henderson DC Copeland PM Daley TB Borba CP Cather C Nguyen DD Louie PM Evins AE Freudenreich O Hayden D Goff DC A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain Am J Psychiatry 2005, 162(5):954-962. 10.1176/appi.ajp.162.5.954 15863798
26. Hoffmann VP Ahl J Meyers A Schuh L Shults KS Collins DM Jensen L Wellness intervention for patients with serious and persistent mental illness J Clin Psychiatry 2005, 66(12):1576-1579. 16401160
27. Vreeland B Minsky S Menza M Rigassio Radler D Roemheld-Hamm B Stern R A program for managing weight gain associated with atypical antipsychotics Psychiatr Serv 2003, 54(8):1155-1157. 10.1176/appi.ps.54.8.1155 12883145
28. Ascher-Svanum H Stensland MD Kinon BJ Tollefson GD Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic J Psychopharm 2005, 19(6 Supplement):110-117. 10.1177/0269881105058978 16280344